NCT00482508View on ClinicalTrials.gov

Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions
Asthma
Interventions
DRUG

Omalizumab

Sponsors

Lead Sponsor

Novartis

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Novartis

INDUSTRY